Drug Trial Radar · NCT01221077
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Apr 8, 2011
Primary completion
Mar 1, 2013
Study completion Sep 1, 2014
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene who are Chemonaive.
Conditions
- NSCLC
- Non Small Cell Lung Cancer
Interventions
OSI-906Drug
As of 01 March 2013, OSI-906 is no longer being administered
ErlotinibDrug
Erlotinib administered orally
PlaceboDrug
As of 01 March 2013, the matching placebo is no longer being administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival of OSI-906 in combination with Erlotinib or Erlotinib plus placeboTime frame: 15 months
Locations
29 sites in 6 countries. Site status is shown where the registry gives one.
University of California, San Diego/Moores Cancer Center
La Jolla, California
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Karmanos Cancer Institute
Detroit, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
Medical University of South Carolina
Charleston, South Carolina
University of Tennessee Cancer Institute
Memphis, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Swedish Cancer Institute
Seattle, Washington
Seattle Cancer Care Alliance University of Washington
Seattle, Washington
Juravinski Cancer Centre
Hamilton, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Pamela Youde Nethersole Eastern Hospital
Chai Wan, Hong Kong
Oncocare Cancer Center
Singapore, Singapore
Johns Hopkins Singapore International Medical Centre
Singapore, Singapore
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Samsung Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Chonnam National University Hwasun Hospital
Ilsimri, Hwasun-gun, South Korea
Asan Medical Center
Songpa-gu, Seoul, South Korea
Maharaj Nakorn Chiangmai
Chiang Mai, Thailand
Khon Kaen University
Khon Kaen, Thailand
Songklanagarind Hospital, Prince of Songkla University
Songkhla, Thailand
National Cancer Institute
Phayathai, Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.